98%
921
2 minutes
20
Background: Impairment of the conduction system is a common complication of transcatheter aortic valve replacement (TAVR), which is typically performed in elderly patients. A leadless pacemaker (LP) may be a suitable option in this frail population, but the available scientific data concerning the efficacy and safety of leadless pacing after TAVR are sparse. The purpose of this analysis was to evaluate the efficacy and safety of LP implantation in patients with relevant bradycardias after TAVR, compared to other indications.
Methods: Consecutive patients were retrospectively enrolled. Demographics, background heart diseases, interventional parameters, and follow-up data were collected.
Results: A total of 257 consecutive patients who underwent LP implantation were included. In 26 patients, the device was implanted due to bradycardias after TAVR (TAVR group), whereas the remaining 231 patients were in the population without previous TAVR (non-TAVR group). The mean implantation duration (56 ± 22 minutes in the TAVR group vs 48 ± 20 minutes in the non-TAVR group; = not significant [NS]) and the implantation success rate (100% in the TAVR group vs 98.7% in the non-TAVR group; = NS) were similar in the 2 cohorts. No significant differences occurred in pacing parameters (sensing, impedance, and threshold, respectively) between the 2 groups, either at implantation or during follow-up. A total of 8 major periprocedural complications (3.1% of patients in total; 3.8% in the TAVR group vs 3.0% in the non-TAVR group; = NS) occurred within 30 days, without significant difference between the 2 groups.
Conclusions: LP implantation appears to be safe and effective in patients after TAVR, and therefore, this procedure is a suitable option for this often old and frail population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994977 | PMC |
http://dx.doi.org/10.1016/j.cjco.2023.10.009 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Introduction: Patients with aortic aneurysms are at elevated risk of rupture, dissection and death during and after transcatheter aortic valve repair (TAVR), often requiring consideration for endovascular aneurysm repair (EVAR) at the time of TAVR. However, data comparing outcomes of simultaneous versus staged TAVR-EVAR are limited.
Methods: Using the National Inpatient Sample between the years 2018 and 2021, we compared in-hospital outcomes of simultaneous and staged TAVR-EVAR.
Cardiovasc Revasc Med
August 2025
Department of Cardiothoracic Surgery, NYU Langone Health, NY, United States of America. Electronic address:
Background: Transcatheter aortic valve replacement (TAVR) has become a cornerstone in the management of aortic valve disease. However, delayed complications after hospital discharge and readmission remain in an issue following TAVR. We aimed to evaluate the impact of remote monitoring systems on clinical outcomes after TAVR.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Oklahoma Heart Hospital, Oklahoma City, Oklahoma, USA.
Transcatheter aortic valve replacement (TAVR) is widely used to treat severe aortic stenosis; however, periprocedural stroke remains a significant concern. This systematic review and meta-analysis evaluate whether the use of cerebral embolic protection devices (CEPDs) during TAVR reduces the risk of stroke and other complications. To conduct a network meta-analysis of relevant trials to assess the efficacy of CEPDs currently used in TAVR.
View Article and Find Full Text PDFNeth Heart J
September 2025
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Background: In recent years, hospital stays after transcatheter aortic valve replacement (TAVR) have shortened. Previous studies have shown that next-day discharge (NDD) is feasible without compromising patient safety, but data from the Dutch hospital setting are lacking. To assess the real-world effect of a NDD policy after TAVR.
View Article and Find Full Text PDFCardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:
Objective: Data remain limited on factors influencing the selection of redo-transcatheter aortic valve replacement (TAVR) versus surgical explant in patients with failing transcatheter heart valves. This study aimed to identify clinical and procedural factors guiding treatment decisions.
Methods: This single-center, retrospective study included all patients who underwent aortic valve reintervention following prior TAVR at a U.